Publications by authors named "C Catellani"
Purpose: PCOS is associated with low grade inflammation which could play a role in insulin resistance and ovarian dysfunction. Preliminary findings suggested that serum levels of HMGB1, a cytokine involved in inflammation, might be altered in women with PCOS. Primary aim of this study was to assess whether HMGB1 serum concentrations are associated with PCOS and with the state of insulin resistance of these women.
View Article and Find Full Text PDFContext: There is growing evidence of the role of epigenetic regulation of growth, and miRNAs potentially play a role.
Objective: The aim of this study is to identify changes in circulating miRNAs following GH treatment in subjects with isolated idiopathic GH deficiency (IIGHD) after the first 3 months of treatment, and verify whether these early changes can predict growth response.
Design And Methods: The expression profiles of 384 miRNAs were analyzed in serum in 10 prepubertal patients with IIGHD (5 M, 5 F) at two time points before starting GH treatment (t-3, t0), and at 3 months on treatment (t+3).
Background And Aim: Cystic fibrosis (CF), is due to CF transmembrane conductance regulator (CFTR) loss of function, and is associated with comorbidities. The increasing longevity of CF patients has been associated with increased cancer risk besides the other known comorbidities. The significant heterogeneity among patients, suggests potential epigenetic regulation.
View Article and Find Full Text PDFArticle Synopsis
- - Bronchial thermoplasty (BT) is a promising treatment for severe asthma, but identifying which patients will benefit the most poses a challenge, and the underlying mechanisms are not fully understood.
- - In a study of 27 severe asthma patients, 81% were considered responders to BT based on improvements in asthma control and medication reduction; specific gene expression changes were observed post-treatment.
- - The findings suggest that BT effectively triggers airway remodeling regardless of asthma endotype, highlighting the potential for certain biomarkers to predict treatment response and clinical outcomes.
Purpose: Treatment of severe asthma has made great strides thanks to rapid progress in understanding immune response and inflammatory pathways. This led to the advent of the first biologic for severe allergic asthma (SAA), omalizumab. Although the long-term efficacy and safety of omalizumab has been confirmed, increasingly longer follow-up data can further reinforce this evidence and potentially provide new ones, for example on any loss of efficacy or the appearance of unexpected side effects.
View Article and Find Full Text PDF